Sienna Diagnostics Initial Public Offering

For information about the Sienna Cancer Diagnostics IPO, click here:


Sienna IPO Information

Investor Snapshot

Sienna identifies, develops and commercialises reagents and in vitro diagnostic tests that target an unmet need. Sienna has built a strong team and a global scientific, clinical, and commercial partner network.

Sienna's first technology platform for the detection of telomerase, has been validated through it's adoption and use at major USA pathology laboratories. 

Current work programs are focussed on:

  • Market penetration of the telomerase technology platform in current IVD registered markets
  • Global market expansion for existing product
  • Scientific R&D both internal and through global partners to research expanded utility of telomerase product 
  • The search for additional biomarkers to feed the Sienna development and commercialisation engine    

 

Name Sienna Cancer Diagnostics Ltd.
Business Description Sienna is a biotechnology company working with a combination of in-licensed and in-house developed intellectual property to deliver in-vitro diagnostic products to the pathology market.
History Formed in 2002, with a change of name (from Sienna Capital Ltd) in 2006, Sienna was originally managed from Sydney. The Company moved its administrative activities to Melbourne in 2006, concurrently bringing R&D activities in-house. Prior to this time, laboratory work was largely carried out at the Ludwig Institute for Cancer Research, where valuable relationships were established.
Shares on issue Approximately 157 million
Share price at last capital raising $0.17 in January / February 2017
Share trading
Expressions of interest to buy or sell are put to the Company Secretary and introductions made, ensuring any transaction occurs independently of Sienna.
Company structure  Public unlisted company with approximately 160 shareholders
Location  Head office and laboratory based at the Small Technologies Cluster, 1 Dalmore Drive, Scoresby, VIC 3179, Australia 
Auditor  Walker Wayland NSW
Chartered Accountants
8th Floor, 55 Hunter St
Sydney, NSW 2000 Australia Tel: +61-2- 9951-5400
www.wwnsw.com.au
Accountant  Deloitte
Level 9, 550 Bourke St
Melbourne, VIC 3000 Australia Tel: +61-3-9671-7000
www.deloitte.com.au
 Corporate Advisors Sequoia Corporate Finance
www.sequoia.com.au/our-group/sequoia-corporate-finance/ 
Company Secretary  Tony Di Pietro 
Share Registry 

Link Market Services
Locked Bag A14
Sydney South, NSW 1235
Australia

Toll-free: 1300-554-474 (Australia only)
International: +61-1300-554-474

www.linkmarketservices.com.au

Investor Documents

Annual Reports are prepared by Sienna and its auditors under Corporations Law each year for the financial year July-June. Copies of annual reports can be viewed here or provided as hard copy if requested at info@siennadiagnostics.com.au

  • Annual report to June 2016
  • Sienna 2015 AGM Resolutions
  • Annual report to June 2015
  • Company constitution 2015
  • Annual report to June 2014
  • Annual report to June 2013
  • Annual report to June 2012
  • Annual report to June 2011
  • Chinese language company overview

Sign up to our newsletter

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059